Item 8.01. Other Events.



On June 10, 2022, BeiGene, Ltd. ("BeiGene") announced that it was presenting
data from its hematology portfolio at the European Hematology Association (EHA)
2022 Hybrid Congress being held June 9-12, 2022, in Vienna, Austria. The full
text of this press release is filed as Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated herein by reference.

On June 10, 2022, BeiGene announced that the China National Medical Products
Administration (NMPA) approved BeiGene's anti-PD-1 antibody, tislelizumab, in
combination with chemotherapy as a first-line treatment for patients with
recurrent or metastatic nasopharyngeal cancer (NPC). The full text of this press
release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is
incorporated herein by reference.

On June 13, 2022, BeiGene announced that the U.S. Food and Drug Administration
(FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date by three
months to January 20, 2023 for the supplementary new drug application (sNDA) for
BRUKINSA as a treatment for adult patients with chronic lymphocytic leukemia
(CLL) or small lymphocytic lymphoma (SLL). The full text of this press release
is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated
herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.            Description

       99.1               Press release titled "BeiGene Highlights Growing Portfolio and Pipeline
                          Targeting Hematologic Malignancies at European

Hematology Association 2022

Congress" issued by BeiGene, Ltd. on June 10,

2022



       99.2               Press release titled "China NMPA Approves

Tislelizumab for Recurrent or


                          Metastatic Nasopharyngeal Cancer" issued by

BeiGene, Ltd. on June 10, 2022



       99.3               Press release titled "BeiGene Announces PDUFA

Goal Date Extension for U.S.


                          sNDA for BRUKINSA for the Treatment of CLL/SLL"

issued by BeiGene, Ltd. on

June 13, 2022

       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses